January 17, 2020
Thanks for a longer weekend, Dr. Martin Luther King and some freedom from markets
Pre-open indications: we are getting overbought
My version of the morning’s numbers is written to be informative; it’s includes what happened or will beyond the headline and shapes today’s markets as seen by RMi - SUBSCRIBE
January 2, 2020
“Last year's words .... belong to last year's language.January 17, 2020
News: The continuing saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of MIT and Harvard and two local startups – Editas Medicine (EDIT -$1.38) and Beam Therapeutics (private) while Intellia Therapeutics (NTLA -$0.53) and CRISPR Therapeutics (CRSP -$1.30) fell alongside
The week in review
Welcome to my world of defining the “grey’ in our universe!
December 6, 2019
Dropping -$89.03 on Thursday and is up +$4.23 or +7.91% on Friday One day removed after shares of SAGE falling -59.7%, the stock is "bouncing" higher in trading after hitting 52-week lows on Thursday.
November 3, 2019
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5; AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6; Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7 …. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
September 11, 2019
We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
January 17, 2020
RegMed Investors’ (RMi) closing bell: the sector slips and slides
January 17, 2020
RegMed Investors’ (RMi) pre-open; TGIF
January 15, 2020
RegMed Investors’ (RMi) closing bell: am I going deaf?
January 15, 2020
RegMed Investors’ (RMi) pre-open; a flat open ahead of US-China deal signing
January 14, 2020
RegMed Investors’ (RMi) closing bell: Dow’s barely up as S&P and NASDAQ dive
January 14, 2020
RegMed Investors’ (RMi) pre-open: day two of JPMorgan healthcare conference
January 13, 2020
RegMed Investors’ (RMi) closing bell: day one (1) of JPMorgan and a share pricing downer
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
